Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Every row

Showing 2 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.

Scroll the table sideways to see every column.

Research and outcomes, 2 rows. Every row links to its source.
Exposure Question Direction Outcome measured Design People Effect size, as the source reported it Source
Modifiable risk factors combined All modifiable factors together Prevention Harm
why

Direction is for carrying the risk factors: the Commission attributes 45% of cases to 14 modifiable factors, which is the same number read the other way as prevention potential. The Commission's own caveat is that "some associations might be only partly causal".

Population attributable fraction of dementia systematic review not stated "estimated that the PAF for all 14 risk factors was 45.3%" (Table 1: overall PAF 45.3%, rounded 45%); high LDL cholesterol unweighted PAF 18.7%, weighted 6.9%, rounded 7%; untreated vision loss unweighted 6.0%, weighted 2.2%, rounded 2% The Lancet 2024
✓ Peer-reviewed PMID 39096926
Anti-amyloid antibody Medicines Treatment Harm
why

The review's subject is the harm itself: brain swelling and microbleeds caused by the drugs.

ARIA incidence and severity systematic review not stated "ARIA-E and ARIA-H occurred in 12.6% and 17.3% of participants on lecanemab, respectively" (CLARITY-AD); "ARIA-E and ARIA-H occurred in 24% and 31% of participants on donanemab, respectively" (TRAILBLAZER-ALZ-2); APOE e4 homozygotes "may have ~2.5 to 5 times greater risk for incident ARIA-E and for ARIA-H" Alzheimer's & Dementia 2026
✓ Peer-reviewed PMID 42015334

How this table was built, and where it is weak →